Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Letter to the Editor
28 March 2024

Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema

Authors: Max Schlueter https://orcid.org/0000-0003-1772-1421 [email protected] and Sandra Nestler-ParrAuthor Info & Affiliations
Volume 13, Number 5
https://doi.org/10.57264/cer-2023-0165
PDFFormats
First page of PDF

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
Watt M, Malmenäs M, Romanus D, Haeussler K. Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema. J. Comp. Eff. Res. 12(6), e220188 (2023).
PubMed
Google Scholar
2.
Banerji A, Busse P, Shennak M et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N. Engl. J. Med. 376(8), 717–728 (2017).
PubMed
Google Scholar
3.
Aygören-Pürsün E, Bygum A, Grivcheva-Panovska V et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. N. Engl. J. Med. 379(4), 352–362 (2018).
PubMed
Google Scholar
4.
Ohsawa I, Honda D, Suzuki Y et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase III randomized trial. Allergy 76(6), 1789–1799 (2021).
PubMed
Google Scholar
5.
Zuraw BL, Busse PJ, White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med. 363(6), 513–522 (2010).
PubMed
Google Scholar
6.
Banerji ARM, Bernstein JA, Cicardi M et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA 320(20), 2108–2121 (2018).
PubMed
Google Scholar
7.
Zuraw B, Lumry WR, Johnston DT et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase III trial. J. Allergy Clin. Immunol. 148(1), 164–172.e9 (2021).
PubMed
Google Scholar
8.
Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162(11), 777–784 (2015).
PubMed
Google Scholar
9.
Izcovich A, Chu DK, Mustafa RA, Guyatt G, Brignardello-Petersen R. A guide and pragmatic considerations for applying GRADE to network meta-analysis. BMJ 381, e074495 (2023).
PubMed
Google Scholar
10.
Nikolakopoulou A, Higgins JPT, Papakonstantinou T et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLOS Med. 17(4), e1003082 (2020).
PubMed
Google Scholar
11.
Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst. Rev. 11(11), Cd013403 (2022).
PubMed
Google Scholar
12.
CADTH Common Drug Review. Clinical Review Report for Lanadelumab (Takhzyro) (Indication for routine prevention of attacks of hereditary angioedema in adolescents and adults). Canadian Agency for Drugs and Technologies in Health, Canada (2020).
Google Scholar
13.
CADTH. CADTH Reimbursement Recommendation. Berotralstat (Orladeyo). Can. J. Health Technol. 3(3), (2023). https://canjhealthtechnol.ca/index.php/cjht/article/view/SR0723/1247
Google Scholar
14.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Berotralstat (hereditäres Angioödem) – Nutzenbewertung gemäß § 35a SGB V. (2021).
Google Scholar
15.
Institute for Clinical and Economic Review. Final Evidence Report – Prophylaxis for Hereditary Angioedema with Lanadelumab and C1 Inhibitors: Effectiveness and Value. (2018).
Google Scholar